Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dermacyd Femina Pocket BR (Lactic Acid)
Dermacyd Femina Pocket BR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dermacyd Femina Pocket BR (Lactic Acid) |
| Name | Type | Description |
|---|---|---|
| Dermacyd Femina Pocket BR (Lactic Acid) | DRUG | Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days |
Inclusion criteria: * Integral skin test in the region; * To use products of the same category; Exclusion criteria: * Lactation or gestation; * Use of anti-inflammatory, anti-histaminic or immunosuppressant drugs; * Cutaneous disease (local or spread) in the evaluation area; * Pathology which may...
Dermacyd Femina Pocket BR is a small molecule product developed by Sanofi, known by the ticker SNY. It is also called Dermacyd Femina Pocket BR (Lactic Acid). It has been studied in a Phase 3 trial in Brazil for hygiene use in healthy adult women.
Dermacyd Femina Pocket BR has been studied for hygiene use. Its Phase 3 trial enrolled healthy female volunteers aged 18 years and older in Brazil. The specific indications for the product have not been disclosed.
Dermacyd Femina Pocket BR is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor associated with the product's clinical development program.
Dermacyd Femina Pocket BR has completed a Phase 3 clinical trial. It is an investigational product and is not described as FDA approved. The completed trial, NCT00794612, was conducted in Brazil and enrolled 30 participants.
Dermacyd Femina Pocket BR has been studied in one clinical trial, NCT00794612, titled "Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability." That Phase 3 trial is completed, enrolled 30 healthy female volunteers aged 18 years and older, and was conducted in Brazil. It was an uncontrolled study.
Yes, Dermacyd Femina Pocket BR is also known as Dermacyd Femina Pocket BR (Lactic Acid). The two names refer to the same Sanofi product, which has been studied in a completed Phase 3 trial for hygiene use.